Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2008

View Archived Issues

MDV-3100 well tolerated, reduces PSA in castration-resistant prostate cancer patients

In vitro and in vivo activity against hepatocellular cancer seen with CUDC-101

PDL BioPharma reports development of anti-TweakR antibody with antitumor activity

Serenex describes discovery of SNX-5422, an Hsp90 inhibitor in phase I development

F-14512 activity depends on polyamine transport system status of tumors

Positive preclinical data of Palomid-529 in models of ocular disorders

Evotec completes acquisition of Renovis

Corcept reports promising results from human microdosing study of CORT-108297

Epix initiates phase IIb clinical trial of PRX-03140 in combination with Aricept

NanoViricides reports initial results from mouse studies of HivCide-I for HIV/AIDS

Antennapedia Trojan peptide-p21 fusion protein inhibits tumor cell growth

Bayer Schering Pharma to market new low-dose oral contraceptive in Europe

TG-100801's clinical evaluation discontinued due to phase IIa results

Catalyst selects second-generation factor VIIa variant as candidate for hemophilia

DiaMedica enrolls final patient in phase DM-83 clinical trial

FDA accepts for review Cinryze complete response submission

QRxPharma releases successful phase III study results for Q-8003-IR

Cadence completes full enrollment in phase III CLIRS clincial trial of Omigard

FDA Advisory Committee recommends against approval of Fentora expanded label

Genentech initiates phase II clinical trial of GDC-0449 in metastatic colorectal cancer

Novel agents for treating autoimmune diseases disclosed in recent Pharmacopeia patents

Targacept designates neuronal nicotinic receptor drug in smoking cessation program

Recent patents claim novel therapeutic agents for psychosis, depression and anxiety

LLS and MannKind enter agreement to develop targeted tyrosine kinase inhibitor

Glenmark launches topical antifungal cream Onabet in India

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...